“…Sixteen trials (70%) were for a single LTC, of these: 13 were for diabetes [23,25,26,[29][30][31][32][33][34][37][38][39]53], two for hypertension [50,51]; and one was for osteoporosis [52]. Eight trials considered multiple LTCs: three were diabetes and hypertension/cardiovascular risk [40][41][42]46]; one was diabetes and depression [43], one was for overweight patients with diabetes [44]; one was chronic pain and depression [22] two in China [32,50] and one each in Australia [31], Germany [51] and the United Kingdom [52]. Twelve trials were measured the effectiveness, impact or efficacy of SMAs compared to usual care [19,22,23,26,29,32,33,38,39,42,46,53], nine trials examined feasibility parameters [24,30,31,34,37,38,…”